EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer

Abstract Background In various cancers, overexpression of cyclooxygenase (COX)-2 and elevated prostaglandin (PG) E2 synthesis have been associated with tumor development and progression. The potential of COX-2 inhibitors in cancer prevention and treatment has been shown repeatedly; however, their cl...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Anna Semmlinger, Viktoria von Schoenfeldt, Verena Wolf, Alexandra Meuter, Theresa Maria Kolben, Thomas Kolben, Christine Zeder-Goess, Florian Weis, Julia Gallwas, Rachel Wuerstlein, Kerstin Hermelink, Elisa Schmoeckel, Nadia Harbeck, Doris Mayr, Sven Mahner, Udo Jeschke, Nina Ditsch
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2018-04-01
Colecção:	BMC Cancer
Assuntos:	Breast cancer EP3 Prostaglandin E2 EP-receptor COX-2 PGE2
Acesso em linha:	http://link.springer.com/article/10.1186/s12885-018-4286-9
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!